Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 20/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3211094 | 0.94 | PDE4B (0.63) | PDE4BCYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL3211091 | 0.94 | PDE4B (0.63) | PDE4BCYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL3204905 | 0.91 | PDE4B (0.60) | PDE4BCYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL7961701 | 0.91 | PDE4B (0.60) | PDE4BCYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL3204902 | 0.91 | PDE4B (0.60) | PDE4BCYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL3203527 | 0.91 | PDE4B (0.64) | PDE4BCYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL3203533 | 0.91 | PDE4B (0.64) | PDE4BCYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL3213125 | 0.87 | PDE4B (0.63) | PDE4BCYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL3213130 | 0.87 | PDE4B (0.63) | PDE4BCYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL18258690 | 0.87 | PDE4B (0.63) | PDE4BCYP3A4CYP2C9CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2778156-B1 | Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states | ASTRAZENECA AB (SE) | 2016-11-30 | — | — | EP | disclosed |
| EP-2778156-A1 | Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states | AstraZeneca AB (Publ) (SE) | 2014-09-17 | — | — | EP | disclosed |
| US-8273774-B2 | Phenoxypyridinylamide compounds | ASTRAZENECA AB (SE) | 2012-09-25 | — | — | US | disclosed |
| US-20100041638-A1 | Chemical Compounds 293 | ASTRAZENECA AB (SE) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041638-A1 | Chemical Compounds 293 | PDE4B, PDE4A, PDE3B | PDE4B 1/4885CYP3A4 92/4885CYP2C9 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.